DURHAM, N.C., June 26, 2015 /PRNewswire/ -- Spyryx Biosciences, Inc., a privately-held biopharmaceutical company developing novel therapeutics for obstructive lung diseases, announced today it has received an award from Cystic Fibrosis Foundation Therapeutics, which will support development of Spyryx' therapeutic peptides for cystic fibrosis (CF).
"We appreciate the generous support of the Cystic Fibrosis Foundation and are looking forward to working closely with them as we advance our program toward clinical development," stated John Taylor, President and CEO of Spyryx.
In the CF lung, the epithelial sodium channels (ENaC) hyperabsorb sodium and water from the surface of the lung airway, leading to dehydration of the mucus layers and reduced airway clearance. Spyryx is developing inhaled peptides, which are designed to potently degrade ENaC, blocking this absorption and returning airway fluid volumes to normal levels, with the goal of restoring proper mucociliary clearance. This therapeutic approach is independent of the genetic mutations that cause the disease and is anticipated to provide a treatment option to the entire CF patient population. In preclinical models, Spyryx' compounds have demonstrated robust restoration of airway fluid volumes with a duration of action that may allow once-daily dosing in the clinic.
For more information about cystic fibrosis, go to www.cff.org.
About Spyryx Biosciences
Spyryx Biosciences is a biopharmaceutical company developing inhaled therapeutics to address severe respiratory diseases via modulation of a novel biological mechanism for regulating airway fluid. Founded in 2013, Spyryx' lead program is in pre-clinical development for cystic fibrosis. Further information regarding Spyryx Biosciences is available at www.spyryxbio.com.
Spyryx Media Contact:
SOURCE Spyryx Biosciences, Inc.